Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Dyne Therapeutics Inc (DYN)

Dyne Therapeutics Inc (DYN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,896,491
  • Shares Outstanding, K 142,825
  • Annual Sales, $ 0 K
  • Annual Income, $ -317,420 K
  • EBIT $ -449 M
  • EBITDA $ -451 M
  • 60-Month Beta 1.30
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.25

Options Overview Details

View History
  • Implied Volatility 121.12% (-4.08%)
  • Historical Volatility 124.72%
  • IV Percentile 50%
  • IV Rank 33.51%
  • IV High 253.75% on 10/21/25
  • IV Low 54.27% on 01/21/25
  • Expected Move (DTE 13) 3.61 (17.81%)
  • Put/Call Vol Ratio 2.37
  • Today's Volume 2,447
  • Volume Avg (30-Day) 271
  • Put/Call OI Ratio 1.09
  • Today's Open Interest 8,296
  • Open Int (30-Day) 8,377
  • Expected Range 16.67 to 23.89

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.76
  • Number of Estimates 8
  • High Estimate -0.59
  • Low Estimate -0.92
  • Prior Year -0.88
  • Growth Rate Est. (year over year) +13.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.02 +19.12%
on 11/07/25
22.29 -9.02%
on 11/28/25
-0.62 (-2.97%)
since 11/05/25
3-Month
11.92 +70.13%
on 09/29/25
25.00 -18.88%
on 10/28/25
+6.06 (+42.62%)
since 09/05/25
52-Week
6.36 +218.87%
on 04/09/25
29.72 -31.75%
on 12/09/24
-7.46 (-26.89%)
since 12/05/24

Most Recent Stories

More News
Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

- Topline data from Registrational Expansion Cohort of DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in DMD on track for December 2025 to support potential submission...

DYN : 20.28 (-1.79%)
Dyne Therapeutics to Present at Upcoming Investor Conferences

WALTHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...

DYN : 20.28 (-1.79%)
Dyne Therapeutics (DYN) Receives a Buy from Morgan Stanley

In a report released yesterday, Michael Ulz from Morgan Stanley reiterated a Buy rating on Dyne Therapeutics, with a price target of $48.00. The company’s shares closed yesterday at $12.65.Elevate Your...

DYN : 20.28 (-1.79%)
Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)

- Robust improvement demonstrated across diverse set of clinical measures - - Patient-reported outcomes support clinical meaningfulness of improvements in function and strength - - Meaningful...

DYN : 20.28 (-1.79%)
Dyne Therapeutics Elects Brian Posner to Board

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement...

DYN : 20.28 (-1.79%)
Dyne Therapeutics Appoints Brian Posner to its Board of Directors

WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...

DYN : 20.28 (-1.79%)
Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy

- Data from ongoing DELIVER trial demonstrated sustained functional improvement through 18 months; results from Registrational Expansion Cohort expected late 2025 - WALTHAM, Mass., Sept. 29, 2025...

DYN : 20.28 (-1.79%)
Dyne Therapeutics to Present at Upcoming Investor Conferences

WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...

DYN : 20.28 (-1.79%)
Stocks Settle Lower as Bond Yields Rise

The S&P 500 Index ($SPX ) (SPY ) on Monday closed down by -0.43%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down by -0.77%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down by -0.31%....

MSTR : 178.99 (-3.77%)
AXGN : 33.32 (+1.42%)
AAPL : 278.78 (-0.68%)
ADI : 281.29 (+1.45%)
GLXY : 25.51 (-7.47%)
LVS : 66.25 (-0.23%)
FN : 478.45 (+1.41%)
WYNN : 125.51 (-0.17%)
$IUXX : 25,692.05 (+0.43%)
COIN : 269.73 (-1.58%)
PFE : 26.03 (+1.28%)
BNTX : 96.25 (+0.26%)
Stocks Turn Mixed on Strength in the Magnificent Seven Megacaps

The S&P 500 Index ($SPX ) (SPY ) today is down by -0.15%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.49%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up by +0.03%. September E-mini...

MSTR : 178.99 (-3.77%)
AXGN : 33.32 (+1.42%)
GOOGL : 321.27 (+1.15%)
AAPL : 278.78 (-0.68%)
MKTX : 167.24 (-0.01%)
GLXY : 25.51 (-7.47%)
FN : 478.45 (+1.41%)
$IUXX : 25,692.05 (+0.43%)
COIN : 269.73 (-1.58%)
ZNH26 : 112-165s (-0.18%)
MSFT : 483.16 (+0.48%)
TSLA : 455.00 (+0.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Dyne Therapeutics Inc. is a muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases. The company's proprietary platform includes FORCE(TM). Dyne Therapeutics Inc. is based in WALTHAM, Mass.

See More

Key Turning Points

3rd Resistance Point 21.66
2nd Resistance Point 21.33
1st Resistance Point 20.80
Last Price 20.28
1st Support Level 19.95
2nd Support Level 19.62
3rd Support Level 19.09

See More

52-Week High 29.72
Fibonacci 61.8% 20.79
Last Price 20.28
Fibonacci 50% 18.04
Fibonacci 38.2% 15.28
52-Week Low 6.36

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar